Table 2 Relationship between TES protein expression and clinicopathological variables in 140 cases of primary GC
Clinicopathological variables | n†| TESTIN cases (%) | p-Value | |
|---|---|---|---|---|
| Â | Â | Positive | Negative | Â |
Age (years) | Â | Â | Â | 0.384 |
   <56 | 68 | 12 (17.5) | 49 (80.3) |  |
   ≥56 | 72 | 17 (23.6) | 55 (76.4) |  |
Gender | Â | Â | Â | 0.886 |
   Female | 45 | 9 (20.0) | 36 (80.0) |  |
   Male | 95 | 20 (21.1) | 75 (78.9) |  |
Tumor size (cm) | Â | Â | Â | 0.789 |
   <5 | 61 | 12 (19.7) | 49 (80.3) |  |
   ≥5 | 79 | 17 (21.6) | 62 (78.4) |  |
T stage | Â | Â | Â | 0.441 |
   T1 | 12 | 1 (8.3) | 11 (91.7) |  |
   T2 | 17 | 2 (11.8) | 15 (88.2) |  |
   T3 | 85 | 19 (22.4) | 66 (77.6) |  |
   T4 | 26 | 7 (26.9) | 19 (73.1) |  |
N stage | Â | Â | Â | 0.520 |
   N0 | 44 | 6 (13.6) | 38 (86.4) |  |
   N1 | 42 | 9 (21.4) | 33 (78.6) |  |
   N2 | 43 | 11 (25.6) | 32 (74.4) |  |
   N3 | 11 | 3 (27.3) | 8 (72.7) |  |
M stage | Â | Â | Â | 0.997 |
   M0 | 111 | 23 (20.7) | 88 (79.3) |  |
   M1 | 29 | 6 (20.7) | 23 (79.3) |  |
Clinical stage | Â | Â | Â | 0.686 |
   I | 17 | 2 (11.8) | 15 (88.2) |  |
   II | 28 | 5 (17.9) | 23 (82.1) |  |
   III | 51 | 11 (21.6) | 40 (78.4) |  |
   IV | 44 | 11 (25.0) | 33 (75.0) |  |
Differentiation | Â | Â | Â | 0.007* |
   Well | 3 | 2 (66.7) | 1 (33.3) |  |
   Moderate | 30 | 12 (40.0) | 18 (60.0) |  |
   Poor | 97 | 13 (13.4) | 84 (86.6) |  |
   Undifferentiated | 10 | 2 (20.0) | 8 (80.0) |  |